Valuation: NGL Fine-Chem Limited

Market Cap 16.22B 171M 153M 142M 128M 240M 243M 1.7B 674M 8.5B 641M 627M 26.97B P/E 2025
32.6x
P/E 2026 26.6x
Enterprise Value 17.01B 179M 161M 148M 135M 251M 255M 1.78B 706M 8.91B 672M 658M 28.27B EV / Sales 2025
1.9x
EV / Sales 2026 2.71x
Free-Float
27.51%
Yield 2025
0.16%
Yield 2026 0.08%
1 day+0.04%
1 week-4.86%
Current month-9.71%
1 month-9.90%
3 months-18.82%
6 months+13.44%
Current year+86.37%
1 week 2,467.6
Extreme 2467.6
2,799
1 month 2,467.6
Extreme 2467.6
3,251
Current year 1,322
Extreme 1322
3,595
1 year 1,261
Extreme 1261
3,595
3 years 962.7
Extreme 962.7
3,595
5 years 962.7
Extreme 962.7
3,595
10 years 220
Extreme 220
3,789.45
Manager TitleAgeSince
Chief Executive Officer 61 2015-06-29
Director of Finance/CFO 50 2009-08-27
Compliance Officer - 2026-02-02
Director TitleAgeSince
Chairman 61 2011-08-11
Director/Board Member 50 2010-07-20
Director/Board Member - 2015-08-04
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-4.86%+73.33%+48.38% 171M
+0.73%+1.69%+57.57%+128.42% 1,143B
+0.80%+5.17%+45.04%+84.40% 647B
+0.41%+0.95%+26.35%+102.62% 506B
-0.26%+1.53%+52.43%+64.94% 384B
-0.70%-5.96%+61.95%+37.27% 350B
+0.53%+2.00%+30.90%+52.92% 293B
-0.07%+1.78%+3.48%+25.64% 265B
+0.75%+3.17%+54.83%+71.83% 242B
+0.31%+4.13%+35.65%+105.61% 197B
Average +0.25%+0.27%+44.15%+72.20% 402.77B
Weighted average by Cap. +0.39%+0.71%+44.79%+87.35%

Financials

2025 2026
Net sales 3.68B 38.77M 34.8M 32.13M 29.14M 54.45M 55.12M 385M 153M 1.93B 146M 142M 6.12B 5.01B 52.74M 47.33M 43.71M 39.63M 74.08M 74.99M 524M 208M 2.63B 198M 194M 8.33B
Net income 211M 2.22M 2M 1.84M 1.67M 3.12M 3.16M 22.1M 8.78M 111M 8.35M 8.17M 351M 481M 5.07M 4.55M 4.2M 3.81M 7.12M 7.2M 50.34M 19.99M 252M 19.02M 18.61M 800M
Net Debt 116M 1.22M 1.09M 1.01M 915K 1.71M 1.73M 12.1M 4.81M 60.64M 4.57M 4.47M 192M 783M 8.24M 7.4M 6.83M 6.19M 11.58M 11.72M 81.89M 32.52M 410M 30.94M 30.27M 1.3B
Projected Income Statement - Annual - NGL Fine-Chem Limited
Logo NGL Fine-Chem Limited
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Employees
498
Date Price Change Volume
26-10-28 ₹2,625.95 +0.04% 102
26-10-27 ₹2,625.00 +0.21% 17
26-10-26 ₹2,619.45 -0.94% 320
26-10-23 ₹2,644.20 -0.43% 451
26-10-22 ₹2,655.75 +1.12% 734
  1. Stock Market
  2. Stocks
  3. NGLFINE Stock